Keywords: Astellas, Medivation, Licensing, Prostate cancer, MDV3100

Astellas acquires rights to Medivation’s MDV3100 for prostate cancer in up to $765 million deal

Article | 27 October 2009

Print This

In yet another mega-dollar drug licensing deal, Japanese major Astellas Pharma has entered into a global agreement to develop and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in